- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02634866
Cardiovascular Response to Exercise in Hypertension (ASSECURE)
Multivariate ASSEssment of CardiovascUlar Response to the Controlled Exercise in Patients With Hypertension - Prospective and Observational Study (ASSECURE Study)
Arterial hypertension (AH) is an important clinical social and economic problem, related to the increased cardiovascular risk. AH is associated with cardiovascular hemodynamic alterations, including left ventricular diastolic dysfunction (LVddf). In consequence of increased blood pressure, the effectiveness of LV as a blood pump decreases and the symptoms of heart failure (HF) may occur. Thus, the identification of noninvasive markers related with the progression from the asymptomatic AH to LVddf/HFpEF would be beneficial.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
We hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, we assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
The study is intended to verify these hypothesis.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Arterial hypertension (AH) is an important clinical social and economic problem, related to the increased cardiovascular risk.
AH is associated with cardiovascular hemodynamic alterations, including left ventricular diastolic dysfunction (LVddf). In consequence of increased blood pressure, the effectiveness of LV as a blood pump decreases and the symptoms of heart failure (HF), even with preserved ejection fraction (HFpEF), may occur. At the early stage, patients' complaints are not specific and difficult to clinical interpretation. As a consequence, these subjects frequently remain undiagnosed. Thus, the identification of noninvasive markers related with the progression from the asymptomatic AH to LVddf/HFpEF would be beneficial.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
The investigators hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, the investigators assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
Aims:
- The identification of the new markers of cardiovascular risk in patients with arterial hypertension..
- The identification of the new markers of progression from normal left ventricular diastolic function to left ventricular diastolic dysfunction.
- The identification of the new noninvasive markers of progression to symptomatic heart failure.
- The evaluation of the feasibility and usefulness of new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry) in the assessment of the cardiovascular hemodynamic response to exercise.
- Multivariate assessment of cardiovascular response to the controlled exercise, taking into account left ventricular diastolic function and symptoms of heart failure.
- The relation between laboratory markers of left ventricular remodeling with resting and exercise (noninvasive) hemodynamics.
The study will be performed in a prospective and observational design. No less than 120 hypertensive subjects will be enrolled.
After recruitment the following assessment will be performed:
- anamnesis and physical examination with anthropometrics (including body composition analysis with use of bioimpedance method);
- electrocardiogram;
- echocardiography (resting), including assessment of left ventricular systolic (2-D left ventricular ejection fraction, longitudinal strain) and diastolic function (including tissue Doppler imaging);
- impedance cardiography (resting);
- Applanation tonometry (resting);
- 24-h Holter-ekg (including heart rate variability analysis);
- 24-h ambulatory blood pressure monitoring;
- flow-mediated dilation of brachial artery (FMD);
- 6-minute walking test (6-MWT);
- Cardiopulmonary exercise test (CPET), supported by hemodynamic monitoring with impedance cardiography and applanation tonometry;
- Quality of life assessment (SF 36 questionnaire);
- Laboratory tests (including creatinine, urea, uric acid, lipids, glucose, microalbuminuria, N-terminal of the prohormone brain natriuretic peptide, galectin-3, copeptin, soluble ST2, Growth differentiation factor 15 (GDF-15), human tissue inhibitor of metalloproteinases 1 (TIMP-1), metalloproteinase 2 (MMP-2), metalloproteinase 9 (MMP-9), syndecan-1).
After 12 months (first control visit) and 24 months (second control visit) the echocardiography and clinical assessment (HF symptoms) will be performed to identify: 1/ patients with new onset LVDdf (among group N); 2/ patients with new onset HF (among group D)
Morover, the follow-up of min 48 months concerning cardiovascular events will be performed (as defined below)
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Mazovia
-
Warsaw, Mazovia, Polonia, 04-141
- Military Institute of Medicine
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- patients of either sex
- age 40-75 years
- arterial hypertension diagnosed ≥3 months before recruitment.
Exclusion Criteria:
- office blood pressure > 160/100 mmHg
- coronary artery disease
- systolic heart failure (LVEF below 45%) and/or severe heart defect (i.e. valvular disease)
- severe pulmonary diseases (COPD stage C/D, uncontrolled asthma, pulmonary hypertension, pulmonary embolism)
- chronic kidney disease (MDRD eGFR<60 ml/min/1.73m2)
- severe inflammatory disease
- severe mental and physical disorders
- polyneuropathy
- obesity with BMI > 40 kg/m2
- life expectancy less than 12 months in the opinion of the physician
- patients' refusal to participate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Group N
The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
|
Group D
The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
|
Group D_HF
The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
complex end-point (death from cardiovascular causes and/or myocardial infarction and/or stroke and/or decompensated heart failure)
Periodo de tiempo: 48 months
|
Any of the following cardiovascular events: death from cardiovascular causes and/or myocardial infarction and/or stroke and/or decompensated heart failure
|
48 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
death from any cause
Periodo de tiempo: 48 months
|
48 months
|
death from cardiovascular causes
Periodo de tiempo: 48 months
|
48 months
|
myocardial infarction
Periodo de tiempo: 48 months
|
48 months
|
decompensated heart failure
Periodo de tiempo: 48 months
|
48 months
|
stroke
Periodo de tiempo: 48 months
|
48 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
new-onset of heart failure after 12 months (in groups N i D)
Periodo de tiempo: 12 months
|
based on questionnaire
|
12 months
|
new-onset of heart failure after 24 months (in groups N i D)
Periodo de tiempo: 24 months
|
based on questionnaire
|
24 months
|
new-onset of left ventricular diastolic dysfunction in echocardiography after 12 months (in group N)
Periodo de tiempo: 12 months
|
12 months
|
|
new-onset of left ventricular diastolic dysfunction in echocardiography after 24 months (in group N)
Periodo de tiempo: 24 months
|
24 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 0000000336
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .